Importance Clinical trial activity in amyotrophic lateral sclerosis (ALS) is dramatically
increasing; as a result, trial modifications have been introduced to improve efficiency …

Importance There is a lack of validated biomarkers for disability progression independent of
relapse activity (PIRA) in multiple sclerosis (MS). Objective To determine how serum glial …

Background and Objectives Neurodegeneration and astrocytic activation are pathologic
hallmarks of progressive multiple sclerosis (MS) and can be quantified by serum …

Despite the success of disease-modifying treatments in relapsing multiple sclerosis, for
many individuals living with multiple sclerosis, progressive disability continues to accrue …

Importance Mechanisms contributing to disability accumulation in multiple sclerosis (MS) are
poorly understood. Blood neurofilament light chain (NfL) level, a marker of neuroaxonal …

Summary Background Neurofilament light chain (NfL), a neuronal cytoskeletal protein that is
released upon neuroaxonal injury, is associated with multiple sclerosis (MS) relapsing …

Background: The clinical relevance of serum glial fibrillary acidic protein (sGFAP)
concentration as a biomarker of MS disability progression independent of acute …

Multiple sclerosis (MS) is an immune-mediated disorder of the central nervous system (CNS)
characterized by chronic inflammation and neurodegeneration, impacting approximately 2.8 …

Background In a recent trial, hydroxychloroquine (HCQ) treatment reduced the expected rate
of disability worsening at 18 months in primary progressive multiple sclerosis (PPMS) …

Background and Objectives The specificity of novel blood biomarkers for multiple sclerosis
(MS)–related neurodegeneration is unclear because neurodegeneration also occurs during …